Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Broadcom Inc (AVGO) vs ClearPoint Neuro Inc (CLPT) Price & Performance

Broadcom IncTrade
ClearPoint Neuro IncTrade

Price performance (Past 24H)

Key statistics

Broadcom Inc vs ClearPoint Neuro Inc — how do they compare? Broadcom Inc trades at $393.36 (market cap $1.85T), while ClearPoint Neuro Inc trades at $16.07 (market cap $478.63M). The key difference: Broadcom Inc is far larger — about 3865.2× ClearPoint Neuro Inc's market cap, and Broadcom Inc pays a 0.67% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.

AVGOCLPT
Market Cap
$1.85T$478.63M
Sector
TechnologyHealth
52-Week High
$481.57$29.60
52-Week Low
$278.59$8.66
Enterprise Value
$1.90T$506.63M
Dividend Yield
0.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Broadcom Inc

Broadcom (AVGO) trades at $384.05, down 3.98% on the day, but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows bullish technical signals with support at $380 and resistance at $392, while fundamentals reveal impressive profitability with 38.85% net margins and 37.28% ROE. Recent analyst coverage remains overwhelmingly positive with 86% buy ratings.

AVGO presents a compelling growth story with AI-driven revenue expansion and strong cash flow generation, though elevated valuation multiples (P/E 63.9) and high debt levels warrant caution. The consensus price target of $509.70 suggests significant upside potential if execution continues, but investors should monitor competitive pressures in the semiconductor space.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Broadcom Inc

Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.

Read more on AVGO

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT